• Top Stories
  • Interviews
  • Business
  • Finance
  • Banking
  • Technology
  • Investing
  • Trading
  • Videos
  • Awards
  • Magazines
  • Headlines
  • Trends
Close Search
00
GBAF LogoGBAF Logo
  • Top Stories
  • Interviews
  • Business
  • Finance
  • Banking
  • Technology
  • Investing
  • Trading
  • Videos
  • Awards
  • Magazines
  • Headlines
  • Trends
GBAF Logo
  • Top Stories
  • Interviews
  • Business
  • Finance
  • Banking
  • Technology
  • Investing
  • Trading
  • Videos
  • Awards
  • Magazines
  • Headlines
  • Trends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking and Finance Review

Global Banking & Finance Review

Company

    GBAF Logo
    • About Us
    • Profile
    • Wealth
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2025 GBAF Publications Ltd - All Rights Reserved.

    ;
    Editorial & Advertiser disclosure

    Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Finance

    Posted By Global Banking and Finance Review

    Posted on May 13, 2025

    Featured image for article about Finance

    A look at the day ahead in European and global markets from Rocky Swift 

    With markets given another reprieve from a global trade war, attention refocuses on more quotidian cues, like economic data and corporate earnings.

    Six weeks into the turmoil spurred by U.S. President Donald Trump's "Liberation Day" tariffs, the recurring lessons seem to be: wait for the details and buy the dip.

    The China and U.S. rapprochement, resulting in a suspension of the worst tariffs between the world's two biggest economies for 90 days, was better than expected, and reverberated in Asian equity markets with strong gains in Japan after a rally in the United States. 

    And while a Trump social media post on Sunday about high U.S. drug prices caused a massive selloff in Japanese pharma shares on Monday, the actual executive order puts the bullseye more on cheaper drugs overseas, prompting a bounce back in healthcare stocks on the Nikkei.

    Keep an eye on the European pharma stock index, which has outperformed the broader index so far this year.

    Trump's comments about a pricey "fat shot drug", presumably speaking of injectable obesity treatments from Novo Nordisk and Eli Lilly, could mean pressure for cost cuts in the U.S. or increases in Europe. 

    Or both. Comments from Bayer AG after first-quarter results today may give a read on how the German healthcare giant plans to navigate the uncertain road ahead.

    The U.S. dollar was slightly weaker in Asia, but still held most of its gains against the yen, euro and Swiss franc after the trade truce was announced.

    The policy whipsaw and doubt about what lies after the next three months remain as drags on investment sentiment. Equity futures point to a muted open in Europe and a backslide in the U.S.

    Analysts are expecting to see a recovery in German investor sentiment when the ZEW economic research institute releases its data for May today, after tariff concerns sent morale to the lowest since the start of the Ukraine war.

    In the U.S., Consumer Price Index (CPI) figures will provide a signal about the timing of potential rate cuts by the U.S. Federal Reserve. Traders are pricing in 57 basis points of cuts this year, down from over 100 basis points in mid-April.

    Key developments that could influence markets on Tuesday:

    - UK employment (March)

    - BoE Governor Andrew Bailey, chief economist Huw Pill speak at separate events

    - Germany ZEW business sentiment (May)

    - U.S. CPI inflation (April)

    - U.S. earnings: Under Armour, Venture Global 

    - European earnings: Bayer, On Holding 

    Trying to keep up with the latest tariff news?

    Our new daily news digest offers a rundown of the top market-moving headlines impacting global trade. Sign up for Tariff Watch here.

    (Editing by Muralikumar Anantharaman)

    Recommended for you

    • Thumbnail for recommended article

    • Thumbnail for recommended article

    • Thumbnail for recommended article

    Why waste money on news and opinions when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe